Shares of Kalvista Pharmaceuticals Inc (NASDAQ:KALV) have been given an average recommendation of “Buy” by the eleven brokerages that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $31.50.
Several equities research analysts have weighed in on the stock. BidaskClub cut shares of Kalvista Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 6th. TheStreet cut shares of Kalvista Pharmaceuticals from a “c-” rating to a “d+” rating in a research report on Thursday, July 11th. Leerink Swann began coverage on shares of Kalvista Pharmaceuticals in a research note on Monday, July 29th. They set an “outperform” rating and a $31.00 price objective for the company. Zacks Investment Research lowered shares of Kalvista Pharmaceuticals from a “buy” rating to a “sell” rating in a report on Wednesday, July 17th. Finally, Roth Capital set a $30.00 target price on shares of Kalvista Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, September 6th.
Shares of NASDAQ:KALV traded down $0.43 during trading on Friday, reaching $16.00. 80,098 shares of the company traded hands, compared to its average volume of 138,455. The firm has a market capitalization of $292.78 million, a price-to-earnings ratio of -11.59 and a beta of 2.11. Kalvista Pharmaceuticals has a 52-week low of $14.50 and a 52-week high of $34.92. The business’s fifty day moving average is $16.01 and its 200-day moving average is $21.37.
Kalvista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Monday, September 9th. The specialty pharmaceutical company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.20. Kalvista Pharmaceuticals had a negative net margin of 144.64% and a negative return on equity of 22.25%. The company had revenue of $3.37 million for the quarter, compared to the consensus estimate of $3.24 million. On average, research analysts forecast that Kalvista Pharmaceuticals will post -2.67 EPS for the current year.
In related news, Director Albert Cha purchased 26,500 shares of Kalvista Pharmaceuticals stock in a transaction that occurred on Friday, July 26th. The shares were bought at an average price of $16.83 per share, for a total transaction of $445,995.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Edward P. Feener sold 3,300 shares of the business’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $18.62, for a total transaction of $61,446.00. Following the transaction, the insider now owns 98,634 shares in the company, valued at approximately $1,836,565.08. The disclosure for this sale can be found here. In the last 90 days, insiders have purchased 145,427 shares of company stock valued at $2,515,550. 21.60% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of KALV. Cubist Systematic Strategies LLC bought a new position in Kalvista Pharmaceuticals during the 2nd quarter valued at approximately $42,000. Strs Ohio bought a new position in shares of Kalvista Pharmaceuticals in the second quarter worth approximately $68,000. Bank of Montreal Can lifted its stake in shares of Kalvista Pharmaceuticals by 28.5% in the first quarter. Bank of Montreal Can now owns 5,824 shares of the specialty pharmaceutical company’s stock worth $166,000 after buying an additional 1,292 shares in the last quarter. Marshall Wace North America L.P. purchased a new stake in shares of Kalvista Pharmaceuticals during the first quarter valued at approximately $175,000. Finally, Virtus ETF Advisers LLC purchased a new stake in shares of Kalvista Pharmaceuticals during the second quarter valued at approximately $297,000. 82.98% of the stock is currently owned by institutional investors and hedge funds.
About Kalvista Pharmaceuticals
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Featured Story: Diluted Earnings Per Share
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.